Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)
Primary Purpose
Gastrointestinal Stromal Tumors
Status
No longer available
Phase
Locations
Study Type
Expanded Access
Intervention
Regorafenib (BAY73-4506)
Sponsored by
About this trial
This is an expanded access trial for Gastrointestinal Stromal Tumors
Eligibility Criteria
Inclusion Criteria:
- Signed Informed consent (IC) and data protection clarification obtained before any specific treatment related procedures. Patients or their legal representative must be able to understand and willing to sign a written IC.
- Male or female patients >= 18 years of age
- Patients with histologically confirmed metastatic and / or unresectable GIST
- At least imatinib and sunitinib as prior treatment regimens with progression on or intolerance to imatinib and sunitinib
- Eastern Cooperative Oncology Group (ECOG) Performance Status of =< 1
- Adequate bone marrow, liver and renal function
- Women of childbearing potential and men must agree to use adequate contraception before entering the program until at least 8 weeks after the last regorafenib administration in the program. The treating physician or a designated associate is requested to advise the patient on how to achieve adequate birth control. Adequate contraception is defined in this program as any medically recommend method (or combination of methods) as per standard of care.
Exclusion Criteria:
- Prior treatment with regorafenib
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting regorafenib
- Pregnant or breast-feeding patients. Women of childbearing potential must have a pregnancy test performed a maximum of 7 days before start of treatment, and a negative result must be documented before start of regorafenib.
- Congestive heart failure New York Heart Association (NYHA) class 2
- Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months)
- Myocardial infarction less than 6 months before start of regorafenib
- Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted)
- Uncontrolled hypertension. (Systolic blood pressure > 140 mmHg or diastolic pressure > 90 mmHg despite optimal medical management)
- Pleural effusion or ascites that causes respiratory compromise (National Cancer Institute's common terminology criteria for adverse events [NCI-CTCAE] v.4.0 Grade >= 2 dyspnea)
- Ongoing infection NCI-CTCAE v.4.0 Grade > 2
- Known history of human immunodeficiency virus (HIV) infection
- Active hepatitis B or C, or chronic hepatitis B or C requiring treatment with antiviral therapy
- Patients with seizure disorder requiring medication
- History of organ allograft
- Patients with evidence or history of any bleeding diathesis, irrespective of severity
- Any hemorrhage or bleeding event NCI-CTCAE v. 4.0 Grade >= 3 within 4 weeks prior to the start of regorafenib
- Non-healing wound, ulcer, or bone fracture
- Renal failure requiring hemo- or peritoneal dialysis
- Dehydration NCI-CTCAE v.4.0 Grade >= 1
- Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the program
- Known hypersensitivity to regorafenib, the drug class, or excipients in the formulation
- Any illness or medical conditions that are unstable or could jeopardize the safety of the patient and his / her compliance in the program
- Interstitial lung disease with ongoing signs and symptoms
- Persistent proteinuria of NCI-CTCAE v.4.0 Grade 3 (> 3.5 g/24 hours)
- Patients unable to swallow oral medications
- Any malabsorption condition
- Unresolved toxicity higher than NCI-CTCAE v.4.0 Grade 1 (excluding alopecia, anaemia, and hypothyroidism) attributed to any prior therapy / procedure
- Concomitant participation or participation within the last 30 days in a clinical trial
- Non-permissible concomitant medications and procedures (systemic anti-cancer therapy including cytotoxic therapy, signal transduction inhibitors, immunotherapy and hormonal therapy or any experimental therapies; Tyrosine Kinase Inhibitors (TKIs); bone marrow transplant or stem cell rescue; use of biologic response modifiers, such as granulocyte colony stimulating factor (G CSF), within 3 weeks prior to entering the program; St John's Wort; grapefruit and grapefruit juice; all traditional medicines with an anti-cancer indication)
Sites / Locations
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01689376
Brief Title
Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)
Official Title
Guidelines for Treatment With Regorafenib in Patients With Gastrointestinal Stromal Tumors (GIST) After Disease Progression on or Intolerance to Imatinib and Sunitinib (Managed Access Program)
Study Type
Expanded Access
2. Study Status
Record Verification Date
August 2016
Overall Recruitment Status
No longer available
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bayer
4. Oversight
5. Study Description
Brief Summary
The purpose of this Managed Access Program is to provide regorafenib to patients diagnosed with metastatic and / or unresectable GIST who have progressed after standard therapy.
Detailed Description
This "Managed Access Program" covers the different types of programs in the participating countries (including compassionate use program, named patient program, cohorts e.g. ATU in France, etc).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastrointestinal Stromal Tumors
7. Study Design
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Regorafenib (BAY73-4506)
Intervention Description
160 mg BAY73-4506, 3 weeks on drug, 1 week off drug
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
99 Years
Eligibility Criteria
Inclusion Criteria:
Signed Informed consent (IC) and data protection clarification obtained before any specific treatment related procedures. Patients or their legal representative must be able to understand and willing to sign a written IC.
Male or female patients >= 18 years of age
Patients with histologically confirmed metastatic and / or unresectable GIST
At least imatinib and sunitinib as prior treatment regimens with progression on or intolerance to imatinib and sunitinib
Eastern Cooperative Oncology Group (ECOG) Performance Status of =< 1
Adequate bone marrow, liver and renal function
Women of childbearing potential and men must agree to use adequate contraception before entering the program until at least 8 weeks after the last regorafenib administration in the program. The treating physician or a designated associate is requested to advise the patient on how to achieve adequate birth control. Adequate contraception is defined in this program as any medically recommend method (or combination of methods) as per standard of care.
Exclusion Criteria:
Prior treatment with regorafenib
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting regorafenib
Pregnant or breast-feeding patients. Women of childbearing potential must have a pregnancy test performed a maximum of 7 days before start of treatment, and a negative result must be documented before start of regorafenib.
Congestive heart failure New York Heart Association (NYHA) class 2
Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months)
Myocardial infarction less than 6 months before start of regorafenib
Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted)
Uncontrolled hypertension. (Systolic blood pressure > 140 mmHg or diastolic pressure > 90 mmHg despite optimal medical management)
Pleural effusion or ascites that causes respiratory compromise (National Cancer Institute's common terminology criteria for adverse events [NCI-CTCAE] v.4.0 Grade >= 2 dyspnea)
Ongoing infection NCI-CTCAE v.4.0 Grade > 2
Known history of human immunodeficiency virus (HIV) infection
Active hepatitis B or C, or chronic hepatitis B or C requiring treatment with antiviral therapy
Patients with seizure disorder requiring medication
History of organ allograft
Patients with evidence or history of any bleeding diathesis, irrespective of severity
Any hemorrhage or bleeding event NCI-CTCAE v. 4.0 Grade >= 3 within 4 weeks prior to the start of regorafenib
Non-healing wound, ulcer, or bone fracture
Renal failure requiring hemo- or peritoneal dialysis
Dehydration NCI-CTCAE v.4.0 Grade >= 1
Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the program
Known hypersensitivity to regorafenib, the drug class, or excipients in the formulation
Any illness or medical conditions that are unstable or could jeopardize the safety of the patient and his / her compliance in the program
Interstitial lung disease with ongoing signs and symptoms
Persistent proteinuria of NCI-CTCAE v.4.0 Grade 3 (> 3.5 g/24 hours)
Patients unable to swallow oral medications
Any malabsorption condition
Unresolved toxicity higher than NCI-CTCAE v.4.0 Grade 1 (excluding alopecia, anaemia, and hypothyroidism) attributed to any prior therapy / procedure
Concomitant participation or participation within the last 30 days in a clinical trial
Non-permissible concomitant medications and procedures (systemic anti-cancer therapy including cytotoxic therapy, signal transduction inhibitors, immunotherapy and hormonal therapy or any experimental therapies; Tyrosine Kinase Inhibitors (TKIs); bone marrow transplant or stem cell rescue; use of biologic response modifiers, such as granulocyte colony stimulating factor (G CSF), within 3 weeks prior to entering the program; St John's Wort; grapefruit and grapefruit juice; all traditional medicines with an anti-cancer indication)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bayer Study Director
Organizational Affiliation
Bayer
Official's Role
Study Director
12. IPD Sharing Statement
Learn more about this trial
Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)
We'll reach out to this number within 24 hrs